

<b>TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT</b> <b>(Under 37 CFR 1.97(b) or 1.97(c))</b>					Docket No. <b>2488.031</b>	
In Re Application Of: <b>SHAI</b>						
Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.	
10/560,727	12/04/05	Unknown	23405	1654	8544	
Title: <b>ANTIMICROBIAL AND ANTICANCER LIPOPEPTIDES</b>						
Address to: <b>Commissioner for Patents</b> <b>P.O. Box 1450</b> <b>Alexandria, VA 22313-1450</b>						
<b>37 CFR 1.97(b)</b>						
1. <input checked="" type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.						
<b>37 CFR 1.97(c)</b>						
2. <input type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:						
<div style="margin-left: 40px;"> <input type="checkbox"/> the statement specified in 37 CFR 1.97(e); </div>						
<b>OR</b>						
<div style="margin-left: 40px;"> <input type="checkbox"/> the fee set forth in 37 CFR 1.17(p). </div>						

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
2488.031

In Re Application of: SHAI

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/560,727	12/04/05	Unknown	23405	1654	8544

Title: ANTIMICROBIAL AND ANTICANCER LIPOPEPTIDES

**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☐ The Director is hereby authorized to charge and credit Deposit Account No. \_\_\_\_\_ as described below.
- ☐ Charge the amount of \_\_\_\_\_
- ☐ Credit any overpayment.
- ☐ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa

\_\_\_\_\_  
(Date)

\_\_\_\_\_  
Signature

\_\_\_\_\_  
Typed or Printed Name of Person Signing Certificate

**Certificate of Mailing by First Class Mail**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

November 6, 2006

\_\_\_\_\_  
(Date)

\_\_\_\_\_  
Signature of Person Mailing Correspondence

JEFF ROTHENBERG, ESQ.

\_\_\_\_\_  
Typed or Printed Name of Person Mailing Certificate

**\*This certificate may only be used if paying by deposit account.**

\_\_\_\_\_  
Signature  
JEFF ROTHENBERG, ESQ., Reg. No.: 26,429  
Attorney for Applicant

Dated: November 6, 2006

HESLIN ROTHENBERG FARLEY & MESITI P.C.  
5 Columbia Circle  
Albany, New York 12203

Telephone: 518-452-5600  
Facsimile: 518-452-5579  
Email: jr@hrfmlaw.com

CC:

<b>Supplementary Information Disclosure Citation</b>  <b>List of references cited by Applicant</b>  (Sheet 1 of 2)	Attorney Docket Number	Application Number <b>10/560,727</b>
	Applicant: <b>Yechiel et al.</b>	
	Filing Date <b>14 December, 2005</b>	Group Art Unit

U.S. PATENT DOCUMENTS							
*Examiner Initial		DOCUMENT NUMBER	ISSUE DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1						

FOREIGN PATENT DOCUMENTS								
*Examiner Initial		DOCUMENT NUMBER	ISSUE DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	B1							

*Examiner Initial	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	C1	ALEXANDER ET AL., "Antifungal resistance trends towards the year 2000. Implications for therapy and new approaches". Drugs. 1997 Nov;54(5):657-78.
	C2	AVRAHAMI ET AL., "Effect of multiple aliphatic amino acids substitutions on the structure, function, and mode of action of diastereomeric membrane active peptides". Biochemistry 2001 October 23;40(42):12591-603.
	C3	AVRAHAMI ET AL., "Conjugation of a magainin analogue with lipophilic acids controls hydrophobicity, solution assembly, and cell selectivity". Biochemistry 2002 Feb 19; 41(7):2254-63.
	C4	BECHINGER, "The structure, dynamics and orientation of antimicrobial peptides in membranes by multidimensional solid-state NMR spectroscopy". Biochim Biophys Acta. 1999 Dec 15;1462(1-2):157-83.
	C5	DENNING DW. "Epidemiology and pathogenesis of systemic fungal infections in the immunocompromised host". J Antimicrob Chemother. 1991 Oct;28 Suppl B:1-16.
	C6	EFRON ET AL., "Direct interaction of dermaseptin S4 aminoheptanoyl derivative with intraerythrocytic malaria parasite leading to increased specific antiparasitic activity in culture". J Biol Chem. 2002 Jul 5;277(27):24067-72. Epub 2002 Apr 5.
	C7	GAVISH ET AL., "Growth inhibition of prostate cancer xenografts by halofuginone". Prostate. 2002 May 1;51(2):73-83.
	C8	GROLL ET AL., "Trends in the postmortem epidemiology of invasive fungal infections at a university hospital". J Infect. 1996 Jul;33(1):23-32.
	C9	HONG ET AL., "Structure and organization of hemolytic and nonhemolytic diastereomers of antimicrobial peptides in membranes". Biochemistry. 1999 Dec 21;38(51):16963-73.
	C10	MERRIFIELD, "Solid phase peptide synthesis". J. Am. Chem. Soc. 1963 January 31; 85: 2149-2154
	C11	MINAMOTO ET AL., "Fungal infections in patients with acquired immunodeficiency syndrome". Med Clin North Am. 1997 Mar;81(2):381-409.
	C12	OREN ET AL., "Selective lysis of bacteria but not mammalian cells by diastereomers

		of melittin: structure-function study". Biochemistry. 1997 Feb 18;36(7):1826-35.
	C13	OREN ET AL., "A repertoire of novel antibacterial diastereomeric peptides with selective cytolytic activity". J Biol Chem. 1997 Jun 6;272(23):14643-9.
	C14	OREN ET AL., "Mode of action of linear amphipathic alpha-helical antimicrobial peptides". Biopolymers. 1998;47(6):451-63.
	C15	PAPO ET AL., "A novel lytic peptide composed of DL-amino acids selectively kills cancer cells in culture and in mice". J Biol Chem. 2003 Jun 6;278(23):21018-23. Epub 2003 Mar 19.
	C16	SHAI ET AL., "Diastereoisomers of cytolysins, a novel class of potent antibacterial peptides". J Biol Chem. 1996 Mar 29;271(13):7305-8.
	C17	TOSSI ET AL., "Amphipathic, alpha-helical antimicrobial peptides". Biopolymers. 2000;55(1):4-30.
	C18	TSUBERY ET AL., "Structure-function studies of polymyxin B nonapeptide: implications to sensitization of gram-negative bacteria". J Med Chem. 2000 Aug 10;43(16):3085-92.
	C19	UNGER ET AL., "The effect of cyclization of magainin 2 and melittin analogues on structure, function, and model membrane interactions: implication to their mode of action". Biochemistry. 2001 May 29;40(21):6388-97.
	C20	WALSH ET AL., "Recent progress and current problems in treatment of invasive fungal infections in neutropenic patients". Infect Dis Clin North Am. 1996 Jun;10(2):365-400.
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>